GlassScriptPhysician profile
Emily Bowman
NPI 1144778754
$659.30
in general payments reported to CMS, 2019-2025
13 companies · $26.08 in 2025
The $26.08 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $400 · 2023: $14.72 · 2025: $26.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $160.31 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $102.86 | 2021-2022 | |
| Amgen INC. | $99.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $73.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.13 | 2021-2022 | |
| Abbvie INC. | $40.35 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $33.76 | 2022 | |
| Alkermes, INC. | $20.72 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.53 | 2022 | |
| Novo Nordisk INC | $14.72 | 2023 | Wegovy |
| Exeltis, USA INC. | $14.26 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.30 | 2022 | |
| Merck Sharp & Dohme LLC | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.